Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PathoGenesis Corp.

Division of Novartis AG
www.pathogenesis.com

Latest From PathoGenesis Corp.

Rediscovering Existing Drugs

There's been a lot of talk lately about unlocking the hidden value from existing products, that is, drugs that have gone all the way from pure discovery, through the FDA regulatory process and into the hands of patients. These are the industry's greatest assets; they've already distinguished themselves from millions of other compounds by passing the myriad tests related to disease relevancy, safety, efficacy, and more safety, since safety isn't ultimately known until drugs disseminate through the treatment population, years after approval. Recently, there's been a shift to applying the industrial revolution in de novo drug discovery--the tools for screening and assaying libraries of random compounds-to existing drugs, as companies look for new products by reprofiling, repurposing, and redirecting the development of old drugs.
BioPharmaceutical Business Strategies

Corus Pharma: Experienced Help Found

Investors are buying into Corus, which is betting that it can find value in anti-infectives and respiratory products that others discarded because of problematic clinical trials.
BioPharmaceutical Strategy

Selected Start-Ups (7/01)

In Vivo summarizes the technologies of these recently founded companies: Aviva Antibody Corp. will produce monoclonal antibodies for the post-genomics research efforts of future corporate partners. Corus Pharma Inc. will focus on the rapid clinical development and regulatory approval of small-molecule drugs for sleep disorders and respiratory diseases. Isogenica Ltd.'s Covalent Display, is an in vitro library technology for rapidly identifying polypeptides with high affinity and specificity for any given target. Liposonix Inc. will use high-intensity ultrasound to remove unwanted subcutaneous fat. Scienion AG will develop "future-oriented" biochips for use in genomics and proteomics research, DNA diagnostics and the drug discovery and development. Xcellsyz Ltd.'s platform for drug discovery and development is based on conditionally immortalized cell lines that retain many of the properties of primary cells.

Chiron at the Crossroads

Three years into a new CEO's regime, Chiron is trying to forge a unique compromise between research and commercial focus and the stability which comes from a diversified business. But Chiron is at a crossroads: its earnings growth, boosted significantly by a now complete cost-reduction program, doesn't look sustainable without major new products. And those Chiron does not appear to have. Moreover, its major shareholder, Novartis, has an option to buy the company and top management fears they will should the stock show significant signs of weakness, brought on, perhaps, by investments (and consequent earnings reductions) in potential high-growth areas. In effect, Chiron managers are afraid to invest significantly for fear of what Novartis will do should the stock price fall. Moreover, to some degree, Chiron is caught by its business diversity: it can't focus its spending on any one area, particularly biopharmaceuticals, without starving its other businesses--but without a significant increase in R&D spending, particularly in the drug unit, observers don't see how Chiron, which has been uniquely unsuccessful with its pipeline projects, can drive the long-term earnings growth it needs.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Novartis AG
  • Senior Management
  • Wilbur H Gantz, Chmn., Pres. & CEO
    Alan R Meyer, EVP, CFO
    A. B Montgomery, MD, EVP, R&D
  • Contact Info
  • PathoGenesis Corp.
    Phone: (206) 467-8100
    201 Elliott Ave.
    Seattle, WA 98119
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register